Susannah's Progress: Two Years of ASO Treatment with Dr. Jennifer Bain and Luke Rosen
Description
Two years of treatment—two years of strength, courage, and blazing a trail for other nano-rare patients! 🎉 Susannah's story was the first shared on the Patient Empowerment Program podcast. Now, two years later, her father, Luke Rosen, and her physician, Dr. Jennifer Bain, detail Susannah’s remarkable progress since beginning regular treatments—highlighting improvements in her motor skills, cognition, energy, and more!
Susannah's Story (May 25, 2022)
Donate
2024 Nano-rare Patient Colloquium
Â
On This Episode We Discuss:
3:10 Susannah's KIF1A mutation
5:50 Luke and his wife Sally changed their careers to help find a treatment for KIF1A
7:23 How Susannah's family first heard of n-Lorem
8:43 Jen on the Columbia University Medical Center team and the decision to treat Susannah
12:25 Luke's experience bringing his daughter to receive an experimental ASO treatment for the first time
14:30 The positive outcomes and observations of Susannah's treatment
26:15 What Dr. Bain has learned since treating Susannah
29:15 Luke on the impact and importance of the little things
31:15 Advice to other parents
35:40 Being part of a community of nano-rare patients and families
Take a glimpse behind the curtain as we offer you a sneak peek of the 2024 Nano-rare Patient Colloquium. We’re thrilled to welcome back longtime biotech journalist and current Features Editor of The Transmitter, Brady Huggett, to the podcast. In an interview with n-Lorem founder and CEO Stan...
Published 10/02/24
Hongene Biotech is a producer of RNA building blocks – the first step for what’s possible in RNA drug-discovery and development. David Butler, Ph.D., Chief Technology Officer of Hongene, joins the Patient Empowerment Program to discuss why Hongene aims to help make RNA medicines accessible and...
Published 09/18/24